RAGE: A single receptor fits multiple ligands

Trends in Biochemical Sciences

Volumn 36, Issue 12, 2011, Pages 625-632

  Fritz, Günter ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; LIGAND; PATTERN RECOGNITION RECEPTOR;

INFLAMMATION; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LIGAND BINDING; MOLECULAR RECOGNITION; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; STATIC ELECTRICITY; STRUCTURE ANALYSIS; SURFACE CHARGE; X RAY CRYSTALLOGRAPHY;

ANIMALS; HUMANS; LIGANDS; MODELS, MOLECULAR; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 82355190210     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2011.08.008     Document Type: Review

References (62)

1. Neeper M., et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 1992, 267:14998-15004.
2. Schmidt A.M., et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 1992, 267:14987-14997.
3. Bierhaus A., Nawroth P.P. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 2009, 52:2251-2263.
4. Hofmann M.A., et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999, 97:889-901.
5. Park L., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 1998, 4:1025-1031.
6. Taguchi A., et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000, 405:354-360.
7. Leclerc E., et al. Binding of S100 proteins to RAGE: an update. Biochim. Biophys. Acta 2009, 1793:993-1007.
8. Yan S.D., et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 1996, 382:685-691.
9. Deane R., et al. RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 2003, 9:907-913.
10. Stürchler E., et al. Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. J. Neurosci. 2008, 28:5149-5158.
11. McDonald D.R., et al. β-Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes. J. Neurosci. 1998, 18:4451-4460.
12. Huttunen H.J., et al. Receptor for advanced glycation end products (RAGE) signaling induces CREB-dependent chromogranin expression during neuronal differentiation. J. Biol. Chem. 2002, 277:38635-38646.
13. Huttunen H.J., et al. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-κB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J. Biol. Chem. 1999, 274:19919-19924.
14. Yan S.D., et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 1994, 269:9889-9897.
15. Huang J.S., et al. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J. Cell. Biochem. 2001, 81:102-113.
16. Andrassy M., et al. Posttranslationally modified proteins as mediators of sustained intestinal inflammation. Am. J. Pathol. 2006, 169:1223-1237.
17. Koch M., et al. Structural basis for ligand recognition and activation of RAGE. Structure 2010, 18:1342-1352.
18. Park H., Boyington J.C. The 1.5Å crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding. J. Biol. Chem. 2010, 285:40762-40770.
19. Dattilo B.M., et al. The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Biochemistry 2007, 46:6957-6970.
20. Matsumoto S., et al. Solution structure of the variable-type domain of the receptor for advanced glycation end products: new insight into AGE-RAGE interaction. Biochemistry 2008, 47:12299-12311.
21. Xue J., et al. Advanced glycation end product recognition by the receptor for AGEs. Structure 2011, 19:722-732.
22. Xie J., et al. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J. Biol. Chem. 2008, 283:27255-27269.
23. Xie J., et al. Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches. J. Biol. Chem. 2007, 282:4218-4231.
24. Wolf S., et al. Expression, purification and fluorine-18 radiolabeling of recombinant S100A4: a potential probe for molecular imaging of receptor for advanced glycation endproducts in vivo?. Amino Acids 2010, 10.1007/s00726-010-0822-x.
25. Allmen E.U., et al. V domain of RAGE interacts with AGEs on prostate carcinoma cells. Prostate 2008, 68:748-758.
26. Ostendorp T., et al. Structural and functional insights into RAGE activation by multimeric S100B. EMBO J. 2007, 26:3868-3878.
27. Garlick R.L., et al. Nonenzymatic glycation of human lens crystallin. Effect of aging and diabetes mellitus. J. Clin. Invest. 1984, 74:1742-1749.
28. Toth C., et al. Diabetes, leukoencephalopathy and rage. Neurobiol. Dis. 2006, 23:445-461.
29. Yan S.F., et al. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev. Mol. Med. 2009, 11:e9.
30. Penfold S.A., et al. Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney Int. 2010, 78:287-295.
31. Riehl A., et al. Identification of the Rage-dependent gene regulatory network in a mouse model of skin inflammation. BMC Genomics 2010, 11:537.
32. Marenholz I., et al. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem. Biophys. Res. Commun. 2004, 322:1111-1122.
33. Fritz G., et al. Natural and amyloid self-assembly of S100 proteins: structural basis of functional diversity. FEBS J. 2010, 277:4578-4590.
34. Yan S.D., et al. RAGE-Aβ interactions in the pathophysiology of Alzheimer's disease. Restor. Neurol. Neurosci. 1998, 12:167-173.
35. Haupt C., et al. Pattern recognition with a fibril-specific antibody fragment reveals the surface variability of natural amyloid fibrils. J. Mol. Biol. 2011, 408:529-540.
36. Bianchi M.E., Manfredi A.A. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol. Rev. 2007, 220:35-46.
37. Banerjee S., et al. The C-terminal acidic tail is responsible for the inhibitory effects of HMGB1 on efferocytosis. J. Leukoc. Biol. 2010, 88:973-979.
38. Tian J., et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 2007, 8:487-496.
39. Chavakis T., et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J. Exp. Med. 2003, 198:1507-1515.
40. 2 integrin Mac-1 on neutrophils. J. Immunol. 1998, 160:1427-1435.
41. Orlova V.V., et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J. 2007, 26:1129-1139.
42. van Zoelen M.A., et al. RAGE during infectious diseases. Front. Biosci. (Schol. Ed.) 2011, 3:1119-1132.
43. Heizmann C.W., et al. S100 proteins: structure, functions and pathology. Front. Biosci. 2002, 7:d1356-d1368.
44. Koch M., et al. Implications on zinc binding to S100A2. Biochim. Biophys. Acta 2007, 1773:457-470.
45. Korndörfer I.P., et al. The crystal structure of the human (S100A8/S100A9)2 heterotetramer, calprotectin, illustrates how conformational changes of interacting alpha-helices can determine specific association of two EF-hand proteins. J. Mol. Biol. 2007, 370:887-898.
46. Moroz O.V., et al. The structure of S100A12 in a hexameric form and its proposed role in receptor signalling. Acta Crystallogr. D 2002, 58:407-413.
47. 2+ are essential for S100A12 protein oligomerization and function. BMC Biochem. 2009, 10:11.
48. Novitskaya V., et al. Oligomeric forms of the metastasis-related Mts1 (S100A4) protein stimulate neuronal differentiation in cultures of rat hippocampal neurons. J. Biol. Chem. 2000, 275:41278-41286.
49. Leclerc E., et al. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J. Biol. Chem. 2007, 282:31317-31331.
50. Ostendorp T., et al. Expression and purification of the soluble isoform of human receptor for advanced glycation end products (sRAGE) from Pichia pastoris. Biochem. Biophys. Res. Commun. 2006, 347:4-11.
51. Chan F.K. Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine 2007, 37:101-107.
52. Kramer J.M., et al. Evidence for ligand-independent multimerization of the IL-17 receptor. J. Immunol. 2006, 176:711-715.
53. Livnah O., et al. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 1999, 283:987-990.
54. Yang Y., et al. Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:1906-1911.
55. Yang J., Reth M. Oligomeric organization of the B-cell antigen receptor on resting cells. Nature 2010, 467:465-469.
56. Yuzawa S., et al. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 2007, 130:323-334.
57. Hudson B.I., et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J. 2008, 22:1572-1580.
58. Hudson B.I., et al. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J. Biol. Chem. 2008, 283:34457-34468.
59. Ishihara K., et al. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett. 2003, 550:107-113.
60. Smith D.K., Xue H. Sequence profiles of immunoglobulin and immunoglobulin-like domains. J. Mol. Biol. 1997, 274:530-545.
61. Bork P., et al. The immunoglobulin fold. Structural classification, sequence patterns and common core. J. Mol. Biol. 1994, 242:309-320.
62. Wa C., et al. Characterization of glycation adducts on human serum albumin by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chim. Acta 2007, 385:48-60.